Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
efgartigimod (ADAPT+) 的长期安全性、耐受性和有效性:一项针对全身型重症肌无力患者的 3 期开放标签扩展研究的中期结果
期刊:Frontiers in Neurology
影响因子:2.8
doi:10.3389/fneur.2023.1284444
Howard, James F Jr; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; De Bleecker, Jan L; Murai, Hiroyuki; Meisel, Andreas; Beydoun, Said R; Pasnoor, Mamatha; Guglietta, Antonio; Van Hoorick, Benjamin; Steeland, Sophie; T'joen, Caroline; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato